BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38188019)

  • 1. Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8
    Deng S; Shi J; Sun Y; Quan Y; Shen Z; Wang Y; Li H; Xu J
    Front Cell Dev Biol; 2023; 11():1297211. PubMed ID: 38188019
    [No Abstract]   [Full Text] [Related]  

  • 2. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion.
    Deng S; Zhang Y; Wang H; Liang W; Xie L; Li N; Fang Y; Wang Y; Liu J; Chi H; Sun Y; Ye R; Shan L; Shi J; Shen Z; Wang Y; Wang S; Brosseau JP; Wang F; Liu G; Quan Y; Xu J
    Cell; 2024 Apr; 187(9):2305-2323.e33. PubMed ID: 38614099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of
    Wang SC; Liao LM; Ansar M; Lin SY; Hsu WW; Su CM; Chung YM; Liu CC; Hung CS; Lin RK
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma].
    Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
    Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
    Front Oncol; 2021; 11():658690. PubMed ID: 34150625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
    Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
    BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAMC2 promotes the proliferation of cancer cells and induce infiltration of macrophages in non-small cell lung cancer.
    Liu M; Cai R; Wang T; Yang X; Wang M; Kuang Z; Xie Y; Zhang J; Zheng Y
    Ann Transl Med; 2021 Sep; 9(17):1392. PubMed ID: 34733944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.
    Zhang R; Ma A
    Gene; 2021 Feb; 770():145337. PubMed ID: 33278551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking.
    Jackutė J; Žemaitis M; Pranys D; Šitkauskienė B; Miliauskas S; Bajoriūnas V; Sakalauskas R
    Medicina (Kaunas); 2015 Nov; 51(5):263-71. PubMed ID: 26674143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCAPG is a prognostic biomarker of immune infiltration in non-small-cell lung cancer.
    Zhou Y; Fan Y; Mao Y; Lou M; Liu X; Yuan K; Tong J
    Biomark Med; 2022 May; 16(7):523-535. PubMed ID: 35199566
    [No Abstract]   [Full Text] [Related]  

  • 15. Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.
    Patel SS; Nota SP; Sabbatino F; Nielsen GP; Deshpande V; Wang X; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2021 Jun; 479(6):1373-1382. PubMed ID: 33273248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Moreno-Ruiz P; Corvigno S; Te Grootenhuis NC; La Fleur L; Backman M; Strell C; Mezheyeuski A; Hoelzlwimmer G; Klein C; Botling J; Micke P; Östman A
    Lung Cancer; 2021 May; 155():10-19. PubMed ID: 33706022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer.
    Su D; Wu G; Xiong R; Sun X; Xu M; Mei Y; Wu X
    Front Oncol; 2021; 11():634059. PubMed ID: 33747957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.